Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048758 | 1.00 | TLR2 (0.51) | TLR2MDM2TLR1KMT2AMDM4 | |
| SCHEMBL27153081 | 0.94 | TLR2 (0.50) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL30771460 | 0.94 | TLR2 (0.50) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL30771405 | 0.94 | TLR2 (0.50) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL31296168 | 0.94 | TLR2 (0.50) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL23447164 | 0.94 | TLR2 (0.52) | TLR2MDM2MDM4TP53BCHE | |
| SCHEMBL30771499 | 0.94 | TLR2 (0.50) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL16112812 | 0.94 | TLR2 (0.58) | TLR2MDM2TLR1KMT2AMDM4 | |
| SCHEMBL12231705 | 0.94 | TLR2 (0.50) | TLR2MDM2TLR1KMT2AMDM4 | |
| SCHEMBL30973621 | 0.94 | TLR2 (0.50) | TLR2MDM2TLR1KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235858-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | ALBANY MOLECULAR RES INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9352049-B2 | Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2968599-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS | Albany Molecular Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160305-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140274951-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274951-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | CD44, CD47, SELPLG | TLR2 827/4885MDM2 2105/4885TLR1 938/4885 |
| US-20160235858-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | CD44, CD47, SELPLG | TLR2 827/4885MDM2 2105/4885TLR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.